Key result
Midframe underexpansion during ACURATE neo2 TAVR is linked to ~278% higher 1-year major event risk.
Why the study?
The occurrence and clinical impact of transcatheter heart valve midframe underexpansion following TAVR are not well understood.
Does midframe underexpansion following TAVR with the ACURATE neo2 device worsen the composite of all-cause mortality, stroke, or rehospitalization at 1 year in patients undergoing TAVR?
Cohort (n=604)
Yes
Does midframe underexpansion following TAVR with the ACURATE neo2 device worsen the composite of all-cause mortality, stroke, or rehospitalization at 1 year in patients undergoing TAVR?
Absolute Event Rate: 39.3% vs 10.4%
p-value: p=< 0.001
Midframe underexpansion following TAVR with the ACURATE neo2 device is associated with a 4-fold increased risk of 1-year mortality, which can be mitigated by postdilatation.
No takes yet. Share an insight, caveat, or question.
Midframe underexpansion was associated with higher 1-year events after ACURATE neo2 TAVR; leaves open whether postdilatation mitigates risk.
Kim et al. (2025) conducted a cohort in Transcatheter aortic valve replacement (TAVR) (n=604). Midframe underexpansion vs. No midframe underexpansion was evaluated on Composite of all-cause mortality, stroke, or rehospitalization at 1 year (p=< 0.001). Midframe underexpansion following TAVR with the ACURATE neo2 device was associated with a higher 1-year rate of mortality, stroke, or rehospitalization (39.3% vs 10.4%; P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: